The Food and Drug Administration (FDA) has responded to MRA on our concerns regarding the confidentiality of marketing research data.
"FDA appreciates the concerns raised by MRA, and agrees with the importance of protecting the confidentiality of personal privacy information, including personally identifiable information, of those persons who participate in consumer surveys or other marketing research. Similarly, FDA understands the importance of protecting confidential commercial information, including trade secret and proprietary information."
MRA had contacted the FDA regarding the agency's sweeping demands for marketing research documents from Phillip Morris USA, Inc. to share our concerns about the need to keep respondents' personal information private and not jeopardize the research process or research trade secrets.
Read the FDA's response.